Found 17 Adenocarcinoma trials
A listing of Adenocarcinoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in …
The purpose of this study is to test the effects of the research study drug Telomelysin (OBP-301) in combination with pembrolizumab in advanced or metastatic gastric or gastroesophageal junction (GEJ) cancer. Eligible subjects are those with advanced or metastatic cancer of the stomach or junction between the stomach and esophagus.
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder for whom previous treatment was not successful or no treatment exists, to find out whether a medicine called BI 907828 helps. BI 907828 is a so-called MDM2 inhibitor that is being developed to …
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib with either ipilimumab or nivolumab on patients and their pancreatic cancer.
To compare the effectiveness of two approaches for the management of BE and LGD, endoscopic surveillance and endoscopic eradication therapy (EET), using accepted clinical endpoints of neoplastic progression [high-grade dysplasia (HGD)/mucosal esophageal adenocarcinoma (EAC)/invasive EAC] as determined by a blinded central adjudication committee
This is a single-arm phase II study of twenty-one subjects with mucinous adenocarcinoma of the colon, rectum, or appendix with prior systemic therapy with a fluoropyrimidine, oxaliplatin, and irinotecan. Treatment will consist of nivolumab every 4 weeks and ipilimumab every 8 weeks until disease progression, unacceptable toxicity, or 2 years …
This study is being done to see if tucatinib with trastuzumab, ramucirumab and paclitaxel works better than ramucirumab and paclitaxel to treat HER2-positive (HER2+) cancer of the gut (stomach or gastroesophageal cancer). This study will also look at what side effects happen when participants take this combination of drugs
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 administered as an IV infusion once every four weeks. Patients with tumor types likely to express NaPi2b were enrolled in dose escalation. Patients with platinum-resistant ovarian cancer and non-small cell lung cancer (adenocarcinoma subtype) are being enrolled in the …
This is a pilot study in patients with histologically proven pancreatic adenocarcinoma who have demonstrated at least stable disease following at least 16 weeks of treatment with platinum-based chemotherapy and are recommended for treatment with a PARP inhibitor with or without additional agents, either as part of their clinical care …
This is a phase 1 study that enrolls subjects with metastatic pancreatic adenocarcinoma. The purpose of this study is to learn about the safety and efficacy of a combination of 4 study drugs: ipilimumab (ipi), nab-paclitaxel (nP), gemcitabine (gem), and hydroxychloroquine (HCQ). This is an open-label, non-randomized, exploratory platform trial …
1 - 10 of 17
- 1
- 2
